フォスフォランバンとベータアドレナージックドライブの相互作用は,心筋病と早期死亡率につながる可能性があります
R Dash1, V Kadambi, A G Schmidt
1Department of Cardiovascular Biology, Millennium Pharmaceuticals Inc, Cambridge, Massachusetts, USA.
Circulation
|February 15, 2001
まとめ
心不全のない状態でも,交感性トーンの上昇は,心筋病を引き起こす可能性があります. この研究は,フォスフォランバンとアドレネルギー駆動が相互作用し,マウスの心不全と早期死亡につながることを示しています.
科学分野:
- 心臓病学 心臓病学
- 分子生物学は分子生物学である.
- 生理学 生理学とは
背景:
- フォスフォランバンは,ベータアドレネルジック刺激の重要な標的であるサルコプラズマ網膜の機能を抑制します.
- 慢性的なベータアドレネルゲン受容体活性が有害である可能性があるが,生理学的共感的トーンの影響は不明である.
研究 の 目的:
- 既存の心不全がない場合の生理学的共感トーンが有害かどうかを調査する.
- フォスフォランバンとアドレネルギー駆動の増加との相互作用を解明する.
主な方法:
- トランスジェニックマウスを生成し,フォスフォランバンを過剰に発現させた.
- 評価された心臓機能,心筋細胞力学,およびカルシウム運動.
- プロプラノロルを投与して,心臓機能と交感性トーンを in vivo で評価する.
主要な成果:
- トランスジェニックマウスは静脈収縮性と心筋細胞機能の低下を示し,これはイソプロテレノールによって逆転した.
- プロプラノロルの投与は心臓機能を低下させ,交感性トーンが強化されたことを示した.
- トランスジェニックマウスの老化は,アデニリルサイクラスの無感化,心不全,早死を引き起こした.
結論:
- カテコアミン刺激の補償的な増加は,心筋不全と早期死亡を引き起こす可能性があります.
- 心臓病発症におけるフォスフォランバンとアドレナージックドライブの間の重要な相互作用を強調しています.
関連する概念動画
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...